Ascendis Pharma A/S reported on March 16, 2026, successful results from their ApproaCH Trial, showing that children treated with TransCon CNP continued to improve in growth after two years, highlighting strong retention and safety in the trial. The treatment has demonstrated significant growth benefits and was well-tolerated in the cohort of 84 children.